CYP2B6 Polymorphisms in Methadone Disposition

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

78 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-11-30

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research study will determine if genetic variation in CYP2B6 affects how the body metabolizes methadone.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Variance of Oral Methadone Dosage: Description of Implicated Factors

NCT00894452

Heroin Dependence

COMPLETED

Drug Interaction & Methadone & Buprenorphine

NCT02045693

Hepatitis C

COMPLETED PHASE1

Comparison of Buprenorphine and Methadone - 3

NCT00000334

Opioid-Related Disorders

COMPLETED PHASE2

Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone

NCT01637922

Hepatitis C

COMPLETED PHASE1

Buprenorphine Maintenance Protocol - 1

NCT00000205

Opioid-Related Disorders

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This investigation determined the influence of CYP2B6 genetic variation, specifically CYP2B6\*6 polymorphism, on clinical methadone plasma concentrations, clearance, and metabolism. The hypothesis was that CYP2B6\*6 heterozygotes or homozygotes would have reduced metabolism and clearance. A secondary objective was to evaluate other less common genotypic variants, when encountered. Healthy volunteers in genotype cohorts CYP2B6\*1/\*1, CYP2B6\*1/\*6 , and CYP2B6\*6/\*6, and also CYP2B6\*4 and CYP2B6\*5 carriers, received single doses of IV and oral methadone. Plasma and urine methadone and metabolite concentrations were determined by tandem mass spectrometry. The primary outcome measure was methadone metabolism, measured as plasma metabolite/patent area under the concentration-time curve ratio and metabolite formation clearance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Methadone arm

1. Intravenous racemic methadone HCl, 6.0 mg bolus
2. Oral deuterated racemic methadone HCl, 11 mg capsule (IND#58,511)

Group Type EXPERIMENTAL

IV racemic methadone HCl

Intervention Type DRUG

IV racemic Methadone HC1 6 mg

Oral racemic methadone HCl

Intervention Type DRUG

oral d5-methadone HCl 11 mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IV racemic methadone HCl

IV racemic Methadone HC1 6 mg

Intervention Type DRUG

Oral racemic methadone HCl

oral d5-methadone HCl 11 mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Each subject must meet all of the following criteria:

* 18-50 yr old
* CYP2B6\*1/\*1, CYP2B6\*1/\*6 or CYP2B6\*6/\*6 genotype
* Good general health with no remarkable medical conditions
* BMI \< 33
* Provided informed consent

Exclusion Criteria

Subjects will not be enrolled if any of the following criteria exist:

* Known history of liver or kidney disease
* Use of prescription or non prescription medications, herbals or foods known to be metabolized by or affect CYP2B6
* Females who are pregnant or nursing
* Known history of drug or alcohol addiction (prior or present addiction or treatment for addiction)
* Direct physical access to and routine handling of addicting drugs in the regular course of duty (this is a routine exclusion from studies of drugs with addiction potential)

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes